<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80613">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903447</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0325</org_study_id>
    <nct_id>NCT01903447</nct_id>
  </id_info>
  <brief_title>Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment</brief_title>
  <official_title>Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Internalizing psychopathologies (IPs) involving depression and anxiety are among the most
      prevalent, costly and disabling illnesses. Treatments for IPs are available but the extent
      to which individual patients respond is quite heterogeneous. Little information exists,
      particularly in the biological domain, which helps to explain individual differences in
      treatment response. IPs share similar patterns of dysfunction within the Fronto-Limbic
      Affect Regulation and Emotional Salience (FLARES) brain circuit, and two commonly used,
      'gold standard' treatments - selective serotonin reuptake inhibitors (SSRIs) and cognitive
      behavioral therapies (CBTs) - are equally effective for both anxiety and depressive
      disorders, and appear to change brain activity in the same areas within the FLARES circuit.
      The overarching goal of the project is delineate what are common versus specific FLARE brain
      targets for SSRI and CBT and identify specific aspects of FLARE dysfunction that might
      better predict response to both and to a specific modality of treatment. This experiment
      integrates emotion and its interaction with cognition across several stages of emotional
      experience, encompassing studies that probe sensitivity to acute and potential threat and
      automatic and volitional forms of affect regulation in relation to the FLARES brain network.

      We will enroll 200 patients presenting to our Mood and Anxiety Disorders Program seeking
      treatment for disabling 'anxiety, worry, depressed mood' (IPs, including those characterized
      as Not Otherwise Specified) and randomize them to a 12-week course of SSRI or CBT.
      Dimensional, transdiagnostic negative valence systems (NVS) constructs, including FLARES
      function, will be measured before and after each treatment. Specifically, the project will
      examine 2 Specific Aims: 1) Where and how do SSRI and CBT treatments exert their effects on
      NVS constructs?; and 2) Which NVS construct can predict the likelihood of success from SSRI
      and CBT treatment? Such findings can be used to guide the right patients to the right
      treatments with the highest likelihood of success. They also elucidate a
      pathophysiologically-driven mechanistic model of where and how treatments work in the brain
      and thus hasten the development of new treatments that target the underlying pathophysiology
      across internalizing conditions.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Brain NVS Construct Measures (Composite)</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Brain: functional magnetic resonance imaging (fMRI) BOLD percent signal change [PSC] within region of interests [ROIs: amygdala, bed nucleus of stria terminalis, striatum, hippocampus, anterior cingulate cortex (including dorsal, rostral, &amp; subgenual subdivisions), anterior insula, ventro/dorso-medial prefrontal cortex, orbitofrontal cortex, ventro/dorso-lateral prefrontal cortex for Emotional Face Assessment Task (EFAT), Emotional Face Interference Task (EFIT), Contextual Threat Task (CTT), Emotion Regulation Task (ERT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain NVS Construct Measures (Composite)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Brain: functional magnetic resonance imaging (fMRI) BOLD percent signal change [PSC] within region of interests [ROIs: amygdala, bed nucleus of stria terminalis, striatum, hippocampus, anterior cingulate cortex (including dorsal, rostral, &amp; subgenual subdivisions), anterior insula, ventro/dorso-medial prefrontal cortex, orbitofrontal cortex, ventro/dorso-lateral prefrontal cortex for Emotional Face Assessment Task (EFAT), Emotional Face Interference Task (EFIT), Contextual Threat Task (CTT), Emotion Regulation Task (ERT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain NVS Construct Measure (Composite)</measure>
    <time_frame>Change from Week 0 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Brain: functional magnetic resonance imaging (fMRI) BOLD percent signal change [PSC] within region of interests [ROIs: amygdala, bed nucleus of stria terminalis, striatum, hippocampus, anterior cingulate cortex (including dorsal, rostral, &amp; subgenual subdivisions), anterior insula, ventro/dorso-medial prefrontal cortex, orbitofrontal cortex, ventro/dorso-lateral prefrontal cortex for Emotional Face Assessment Task (EFAT), Emotional Face Interference Task (EFIT), Contextual Threat Task (CTT), Emotion Regulation Task (ERT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electroencephalography (EEG) NVS Construct Measures (Composite)</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Electroencephalography (EEG), event-related potential, late positive potential at centro-posterior sites &amp; Feedback Related Negativity magnitude at centro-frontal sites for Emotional Face Perception Task (EFPT) &amp; Loss Signal Task respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electroencephalography (EEG) NVS Construct Measures (Composite)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Electroencephalography (EEG), event-related potential, late positive potential at centro-posterior sites &amp; Feedback Related Negativity magnitude at centro-frontal sites for Emotional Face Perception Task (EFPT) &amp; Loss Signal Task respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electroencephalography (EEG) NVS Construct Measures (Composite)</measure>
    <time_frame>Change from Week 0 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Electroencephalography (EEG), event-related potential, late positive potential at centro-posterior sites &amp; Feedback Related Negativity magnitude at centro-frontal sites for Emotional Face Perception Task (EFPT) &amp; Loss Signal Task respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiology NVS Construct Measure</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Startle magnitude for Threat Sensitivity Task (TST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiology NVS Construct Measure</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Startle magnitude for Threat Sensitivity Task (TST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiology NVS Construct Measure</measure>
    <time_frame>Change from Week 0 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Startle magnitude for Threat Sensitivity Task (TST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiology NVS Construct Measure 2</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skin conductance response for Fear Extinction &amp; Recall Task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiology NVS Construct Measure 2</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skin conductance response for Fear Extinction &amp; Recall Task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiology NVS Construct Measures 2</measure>
    <time_frame>Change from Week 0 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skin conductance response for Fear Extinction &amp; Recall Task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavior NVS Construct Measures (Composite)</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accuracy &amp; response times for EFAT, EFIT, EFPT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavior NVS Construct Measures (Composite)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accuracy &amp; response times for EFAT, EFIT, EFPT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavior NVS Construct Measures (Composite)</measure>
    <time_frame>Change from Week 0 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accuracy &amp; response times for EFAT, EFIT, EFPT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavior NVS Construct Measures 2 (Composite)</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Affect &amp; expectancy ratings for ERT, CTT, TST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavior NVS Construct Measures 2 (Composite)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Affect &amp; expectancy ratings for ERT, CTT, TST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavior NVS Construct Measures (Composite)</measure>
    <time_frame>Change from Week 0 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Affect &amp; expectancy ratings for ERT, CTT, TST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes Measure 1</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dichotomous variable: Treatment Received (SSRI or CBT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome Measures 2 (Composite)</measure>
    <time_frame>Week 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Continuous variable: Extent of Clinical Improvement in terms of change in IP severity in terms of Interview for Mood and Anxiety Symptoms (IMAS), Inventory for Depression and Anxiety Symptoms (IDAS) and Depression, Anxiety, and Stress Scale (DASS) scores (primary) and Overall Anxiety Severity and Impairment Scale (OASIS), Overall Depression Severity and Impairment Scale (ODSIS), Clinical Global Impression Scale (CGI-S), Global Assessment of Functioning (GAF), and Multidimensional Scale of Independent Functioning (MSIF) (secondary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome Measures 2 (Composite)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Continuous variable: Extent of Clinical Improvement in terms of change in IP severity in terms of Interview for Mood and Anxiety Symptoms (IMAS), Inventory for Depression and Anxiety Symptoms (IDAS) and Depression, Anxiety, and Stress Scale (DASS) scores (primary) and Overall Anxiety Severity and Impairment Scale (OASIS), Overall Depression Severity and Impairment Scale (ODSIS), Clinical Global Impression Scale (CGI-S), Global Assessment of Functioning (GAF), and Multidimensional Scale of Independent Functioning (MSIF) (secondary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome Measures 2 (Composite)</measure>
    <time_frame>Change from Week 0 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Continuous variable: Extent of Clinical Improvement in terms of change in IP severity in terms of Interview for Mood and Anxiety Symptoms (IMAS), Inventory for Depression and Anxiety Symptoms (IDAS) and Depression, Anxiety, and Stress Scale (DASS) scores (primary) and Overall Anxiety Severity and Impairment Scale (OASIS), Overall Depression Severity and Impairment Scale (ODSIS), Clinical Global Impression Scale (CGI-S), Global Assessment of Functioning (GAF), and Multidimensional Scale of Independent Functioning (MSIF) (secondary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome Measures 3 (Composite)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dichotomous/Ordinal: Responder Status ('Significant Responder' [eg, Â³50% reduction in IMAS, IDAS, and/or DASS score and CGI-I score of 1 or 2]); 'Minimal Responder' [eg, 20-49% reduction in IMAS, IDAS, and/or DASS score and CGI-I score of 3) or 'Non-Responder' [&lt;20% reduction in IMAS, IDAS, and/or DASS score and CGI-I score of &gt;3)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Internalizing Psychopathologies (IPs) Depression and Anxiety</condition>
  <arm_group>
    <arm_group_label>SSRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 weeks of individual cognitive behavioral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRI</intervention_name>
    <arm_group_label>SSRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT</intervention_name>
    <arm_group_label>CBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally medically and neurologically healthy

          -  Chief complaint(s) of &quot;anxiety, worry, and/or depressed mood

        Exclusion Criteria:

          -  Current or past manic/hypomanic episode or psychotic symptoms

          -  Suicidal ideation

          -  Presence of contraindications (e.g., history of SSRI adverse events) or      prior
             history of SSRI resistance (no response to &gt; 2 SSRI trials with adequate duration and
             dose)

          -  Obsessive compulsive disorder (OCD)

          -  Current cognitive dysfunction (traumatic brain injury, mental retardation, dementia)

          -  Active alcohol and substance dependence

          -  Ongoing therapy/medication treatment of any kind outside of this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K. Luan Phan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Kennedy, LCSW</last_name>
    <phone>1-888-686-5591</phone>
    <email>emotion@psych.uic.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 16, 2013</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois</investigator_affiliation>
    <investigator_full_name>K. Luan Phan, MD</investigator_full_name>
    <investigator_title>Professor of Psychiatry, Director</investigator_title>
  </responsible_party>
  <keyword>Internalizing psychopathologies</keyword>
  <keyword>Depression</keyword>
  <keyword>Anxiety</keyword>
  <keyword>MRI</keyword>
  <keyword>medication treatment</keyword>
  <keyword>psychotherapy</keyword>
  <keyword>brain function</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
